药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Ranibizumab
Mestranol
The metabolism of Pitavastatin can be decreased when combined with Mestranol.
Ranibizumab
Hydrocortisone phosphate
The metabolism of Pitavastatin can be increased when combined with Hydrocortisone phosphate.
Ranibizumab
Prednisolone phosphate
The metabolism of Pitavastatin can be increased when combined with Prednisolone phosphate.
Ranibizumab
Hydrocortisone butyrate
The metabolism of Pitavastatin can be increased when combined with Hydrocortisone butyrate.
Ranibizumab
Cenobamate
The metabolism of Pitavastatin can be increased when combined with Cenobamate.
Ranibizumab
Hydrocortisone succinate
The metabolism of Pitavastatin can be increased when combined with Hydrocortisone succinate.
Ranibizumab
Hydrocortisone acetate
The metabolism of Pitavastatin can be increased when combined with Hydrocortisone acetate.
Ranibizumab
Rifamycin
The metabolism of Pitavastatin can be increased when combined with Rifamycin.
Ranibizumab
Methylene blue
The metabolism of Pitavastatin can be decreased when combined with Methylene blue.
Ranibizumab
Favipiravir
The metabolism of Pitavastatin can be decreased when combined with Favipiravir.
Ranibizumab
Candesartan
The metabolism of Pitavastatin can be decreased when combined with Candesartan.
Ranibizumab
Triclabendazole
The metabolism of Pitavastatin can be decreased when combined with Triclabendazole.
Ranibizumab
Opicapone
The metabolism of Pitavastatin can be decreased when combined with Opicapone.
Ranibizumab
Nilvadipine
The metabolism of Pitavastatin can be decreased when combined with Nilvadipine.
Ranibizumab
Midostaurin
The metabolism of Pitavastatin can be decreased when combined with Midostaurin.
Ranibizumab
Licofelone
The metabolism of Pitavastatin can be decreased when combined with Licofelone.
Ranibizumab
Rutin
The metabolism of Pitavastatin can be decreased when combined with Rutin.
Ranibizumab
Deferasirox
The metabolism of Pitavastatin can be decreased when combined with Deferasirox.
Ranibizumab
Emetine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pitavastatin is combined with Emetine.
Ranibizumab
Ipecac
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pitavastatin is combined with Ipecac.